WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Monday, May 28, 2007

Hide?	Set Name	Query	Hit Count
	DB=USPT; PLUR=YES; OP=OR		
☐	L12	5264557.pn.	1
☐	L11	6270777.pn.	1
☐	L10	6544518 .pn.	1
☐	L9	cripto.clm.	11
☐	L8	5650285.pn.	1
	DB=EPAB,DWPI; PLUR=YES; OP=OR		
☐	L7	5650285.pn.	1
☐	L6	"Sanicola-Nadel"	27
☐	L5	wo000222808$	0
	DB=EPAB; PLUR=YES; OP=OR		
☐	L4	wo000222808$	0
	DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=OR		
☐	L3	5620866.pn.	2
☐	L2	5264557.pn.	2
☐	L1	6812339.pn.	2

END OF SEARCH HISTORY

RESULT 1
US-10-390-566-2
; Sequence 2, Application US/10390566
; Publication No. US20030232755A1
; GENERAL INFORMATION:
; APPLICANT: Williams, Kevin P.
; APPLICANT: Foley, Susan
; APPLICANT: Schiffer, Susan
; APPLICANT: Domon, Bruno
; APPLICANT: Sanicola-Nadel, Michele
; TITLE OF INVENTION: Cripto Mutant and Uses Thereof
; FILE REFERENCE: BGN-A104
; CURRENT APPLICATION NUMBER: US/10/390,566
; CURRENT FILING DATE: 2003-03-17
; PRIOR APPLICATION NUMBER: 60/233,148
; PRIOR FILING DATE: 2000-09-18
; PRIOR APPLICATION NUMBER: PCT/US01/29066
; PRIOR FILING DATE: 2001-09-18
; NUMBER OF SEQ ID NOS: 37
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 188
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-390-566-2

Query Match 100.0%; Score 188; DB 4; Length 188;
Best Local Similarity 100.0%; Pred. No. 3.8e-179;
Matches 188; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
  Query Match             100.0%;  Score 188;  DB 4;  Length 188;
  Best Local Similarity   100.0%;  Pred. No. 3.8e-179;
  Matches  188;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MDCRKMVRFSYSVIWIMAISKAFELGLVAGLGHQEFARPSRGDLAFRDDSIWPQEEPAIR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MDCRKMVRFSYSVIWIMAISKAFELGLVAGLGHQEFARPSRGDLAFRDDSIWPQEEPAIR 60

Qy         61 PRSSQRVLPMGIQHSKELNRTCCLNGGTCMLESFCACPPSFYGRNCEHDVRKENCGSVPH 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 PRSSQRVLPMGIQHSKELNRTCCLNGGTCMLESFCACPPSFYGRNCEHDVRKENCGSVPH 120

Qy        121 DTWLPKKCSLCKCWHGQLRCFPQAFLPGCDGLVMDEHLVASRTPELPPSARTTTFMLAGI 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 DTWLPKKCSLCKCWHGQLRCFPQAFLPGCDGLVMDEHLVASRTPELPPSARTTTFMLAGI 180

Qy        181 CLSIQSYY 188
              ||||||||
Db        181 CLSIQSYY 188
```

RESULT 1
US-09-949-016-7062
; Sequence 7062, Application US/09949016
; Patent No. 6812339
; GENERAL INFORMATION:
; APPLICANT: VENTER, J. Craig et al.

; TITLE OF INVENTION: POLYMORPHISMS IN KNOWN GENES ASSOCIATED
; TITLE OF INVENTION: WITH HUMAN DISEASE, METHODS OF DETECTION AND USES THEREOF
; FILE REFERENCE: CL001307
; CURRENT APPLICATION NUMBER: US/09/949,016
; CURRENT FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/241,755
; PRIOR FILING DATE: 2000-10-20
; PRIOR APPLICATION NUMBER: 60/237,768
; PRIOR FILING DATE: 2000-10-03
; PRIOR APPLICATION NUMBER: 60/231,498
; PRIOR FILING DATE: 2000-09-08
; NUMBER OF SEQ ID NOS: 207012
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 7062
; LENGTH: 192
; TYPE: PRT
; ORGANISM: Human
US-09-949-016-7062

```
  Query Match             100.0%;  Score 1048;  DB 2;  Length 192;
  Best Local Similarity   100.0%;  Pred. No. 4.7e-100;
  Matches  188;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MDCRKMVRFSYSVIWIMAISKAFELGLVAGLGHQEFARPSRGDLAFRDDSIWPQEEPAIR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          5 MDCRKMVRFSYSVIWIMAISKAFELGLVAGLGHQEFARPSRGDLAFRDDSIWPQEEPAIR 64

Qy         61 PRSSQRVLPMGIQHSKELNRTCCLNGGTCMLESFCACPPSFYGRNCEHDVRKENCGSVPH 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         65 PRSSQRVLPMGIQHSKELNRTCCLNGGTCMLESFCACPPSFYGRNCEHDVRKENCGSVPH 124

Qy        121 DTWLPKKCSLCKCWHGQLRCFPQAFLPGCDGLVMDEHLVASRTPELPPSARTTTFMLAGI 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        125 DTWLPKKCSLCKCWHGQLRCFPQAFLPGCDGLVMDEHLVASRTPELPPSARTTTFMLAGI 184

Qy        181 CLSIQSYY 188
              ||||||||
Db        185 CLSIQSYY 192
```

RESULT 2
US-07-749-001-5
; Sequence 5, Application US/07749001
; Patent No. 5264557
; GENERAL INFORMATION:
; APPLICANT: Salomon, David S.
; APPLICANT: Persico, Maria G.
; TITLE OF INVENTION: A HUMAN CRIPTO-RELATED GENE
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: CUSHMAN, DARBY & CUSHMAN
; STREET: 1615 L Street, N.W.
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/749,001
; FILING DATE: 19910823
; CLASSIFICATION: 435

; ATTORNEY/AGENT INFORMATION:
; NAME: Scott, Watson T.
; REGISTRATION NUMBER: 26,581
; REFERENCE/DOCKET NUMBER: WTS/5683/91630/SRL
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 861-3000
; TELEFAX: (202)822-0944
; TELEX: 248453 CUSH
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 188 amino acids
; TYPE: AMINO ACID
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-07-749-001-5

```
  Query Match             98.6%;  Score 1033;  DB 1;  Length 188;
  Best Local Similarity   98.9%;  Pred. No. 1.6e-98;
  Matches  186;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy          1 MDCRKMVRFSYSVIWIMAISKAFELGLVAGLGHQEFARPSRGDLAFRDDSIWPQEEPAIR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MDCRKMVRFSYSVIWIMAISKAFELGLVAGLGHQEFARPSRGDLAFRDDSIWPQEEPAIR 60

Qy         61 PRSSQRVLPMGIQHSKELNRTCCLNGGTCMLESFCACPPSFYGRNCEHDVRKENCGSVPH 120
              |||||||||||||||||||||||| ||||| ||||||||||||||||||||||||||||||
Db         61 PRSSQRVLPMGIQHSKELNRTCCLNEGTCMLGSFCACPPSFYGRNCEHDVRKENCGSVPH 120

Qy        121 DTWLPKKCSLCKCWHGQLRCFPQAFLPGCDGLVMDEHLVASRTPELPPSARTTTFMLAGI 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 DTWLPKKCSLCKCWHGQLRCFPQAFLPGCDGLVMDEHLVASRTPELPPSARTTTFMLAGI 180

Qy        181 CLSIQSYY 188
              ||||||||
Db        181 CLSIQSYY 188
```

RESULT 3
US-08-154-198-5
; Sequence 5, Application US/08154198
; Patent No. 5620866
; GENERAL INFORMATION:
; APPLICANT: SALOMON, David S.
; APPLICANT: PERSICO, Maria G.
; TITLE OF INVENTION: A HUMAN CRIPTO-RELATED GENE
; NUMBER OF SEQUENCES: 5
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend Khourie and Crew
; STREET: Steuart Street Tower, One Market Plaza
; CITY: San Francisco
; STATE: California
; COUNTRY: US
; ZIP: 94105-1493
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/154,198
; FILING DATE: 17-NOV-1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/749,001
; FILING DATE: 23-AUG-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Bastian, Kevin L.
; REGISTRATION NUMBER: 34,774

; REFERENCE/DOCKET NUMBER: 15280-63-1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 543-9600
; TELEFAX: (415) 543-5043
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 188 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-154-198-5

```
  Query Match             98.6%;  Score 1033;  DB 1;  Length 188;
  Best Local Similarity   98.9%;  Pred. No. 1.6e-98;
  Matches  186;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy          1 MDCRKMVRFSYSVIWIMAISKAFELGLVAGLGHQEFARPSRGDLAFRDDSIWPQEEPAIR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MDCRKMVRFSYSVIWIMAISKAFELGLVAGLGHQEFARPSRGDLAFRDDSIWPQEEPAIR 60

Qy         61 PRSSQRVLPMGIQHSKELNRTCCLNGGTCMLESFCACPPSFYGRNCEHDVRKENCGSVPH 120
              |||||||||||||||||||||||| ||||| ||||||||||||||||||||||||||||
Db         61 PRSSQRVLPMGIQHSKELNRTCCLNEGTCMLGSFCACPPSFYGRNCEHDVRKENCGSVPH 120

Qy        121 DTWLPKKCSLCKCWHGQLRCFPQAFLPGCDGLVMDEHLVASRTPELPPSARTTTFMLAGI 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 DTWLPKKCSLCKCWHGQLRCFPQAFLPGCDGLVMDEHLVASRTPELPPSARTTTFMLAGI 180

Qy        181 CLSIQSYY 188
              ||||||||
Db        181 CLSIQSYY 188
```

RESULT 2
A30362
teratocarcinoma-derived growth factor 1 - human
N;Alternate names: CRIPTO protein
C;Species: Homo sapiens (man)
C;Date: 18-Oct-1989 #sequence_revision 18-Oct-1989 #text_change 09-Jul-2004
C;Accession: B39787; A30362
R;Dono, R.; Montuori, N.; Rocchi, M.; De Ponti-Zilli, L.; Ciccodicola, A.; Persico, M.G.
Am. J. Hum. Genet. 49, 555-565, 1991
A;Title: Isolation and characterization of the CRIPTO autosomal gene and its X-linked related sequence.
A;Reference number: A39787; MUID:91353571; PMID:1882841
A;Accession: B39787
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-188 <DON>
A;Cross-references: UNIPROT:P13385; UNIPARC:UPI000004966D; GB:M96955; GB:M37099; NID:g339430; PID:g339431
R;Ciccodicola, A.; Dono, R.; Obici, S.; Simeone, A.; Zollo, M.; Persico, M.G.
EMBO J. 8, 1987-1991, 1989
A;Title: Molecular characterization of a gene of the 'EGF family' expressed in undifferentiated human NTERA2 teratocarcinoma cells.
A;Reference number: A30362; MUID:90005403; PMID:2792079
A;Accession: A30362
A;Molecule type: mRNA
A;Residues: 1-188 <CIC>
A;Cross-references: UNIPARC:UPI000004966D; GB:X14253; NID:g30220; PIDN:CAA32467.1; PID:g30221
C;Superfamily: teratocarcinoma-derived growth factor 1; EGF homology
C;Keywords: growth factor
F;78-106/Domain: EGF homology <EGF>

```
  Query Match             96.7%;  Score 1013;  DB 2;  Length 188;
  Best Local Similarity   96.8%;  Pred. No. 2e-86;
  Matches  182;  Conservative    0;  Mismatches    6;  Indels    0;  Gaps    0;

Qy          1 MDCRKMVRFSYSVIWIMAISKAFELGLVAGLGHQEFARPSRGDLAFRDDSIWPQEEPAIR 60
              ||||||  |||||||||||||| |||||||||||||||||| ||||||||||||||||
Db          1 MDCRKMARFSYSVIWIMAISKVFELGLVAGLGHQEFARPSRGYLAFRDDSIWPQEEPAIR 60

Qy         61 PRSSQRVLPMGIQHSKELNRTCCLNGGTCMLESFCACPPSFYGRNCEHDVRKENCGSVPH 120
              |||||||  |||||||||||||||||||||| |||||||||||||||||||||||||||
Db         61 PRSSQRVPPMGIQHSKELNRTCCLNGGTCMLGSFCACPPSFYGRNCEHDVRKENCGSVPH 120

Qy        121 DTWLPKKCSLCKCWHGQLRCFPQAFLPGCDGLVMDEHLVASRTPELPPSARTTTFMLAGI 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| ||
Db        121 DTWLPKKCSLCKCWHGQLRCFPQAFLPGCDGLVMDEHLVASRTPELPPSARTTTFMLVGI 180

Qy        181 CLSIQSYY 188
              ||||||||
Db        181 CLSIQSYY 188
```

ESULT 1
ABB77102
ID ABB77102 standard; protein; 188 AA.
XX
AC ABB77102;
XX
DT 08-OCT-2002 (first entry)
XX
DE Human Cripto-3 full length protein.
XX
KW Human; Cripto-1; CR-1; mutant; tumour; Cripto-3; CR-3;
KW cell proliferation.
XX
OS Homo sapiens.
XX
PN WO200222808-A2.
XX
PD 21-MAR-2002.
XX
PF 18-SEP-2001; 2001WO-US029066.
XX
PR 18-SEP-2000; 2000US-0233148P.
XX
PA (BIOJ) BIOGEN INC.
XX
PI Williams KP, Foley S, Schiffer S, Domon B, Sanicola-Nadel M;
XX
DR WPI; 2002-339868/37.
DR N-PSDB; ABB55853.
XX
PT New mutant form of CRIPTO (teratocarcinoma-derived growth factor), useful
PT for treating cell proliferation, especially cancer, comprises amino acid
PT change that prevents fucosylation at Thr88.
XX
PS Claim 2; Fig 1; 41pp; English.
XX
CC The sequence represents the full length human Cripto-3 protein. The
CC invention relates to a novel mutant CRIPTO polypeptide, or its functional
CC fragment, having at least one amino acid alteration at positions 86, 87
CC or 88. The mutant polypeptide, or its chimera, is used to inhibit growth
CC of tumour cells, in vivo or in vitro, particularly for treating breast,
CC ovarian, renal, colorectal, uterine, prostatic, lung, bladder or central
CC nervous system cancers, melanoma and leukaemia, also generally for
CC treating undesired cell proliferation
XX
```
```

SQ Sequence 188 AA;

```
  Query Match             100.0%;  Score 1048;  DB 5;  Length 188;
  Best Local Similarity   100.0%;  Pred. No. 4.7e-85;
  Matches  188;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MDCRKMVRFSYSVIWIMAISKAFELGLVAGLGHQEFARPSRGDLAFRDDSIWPQEEPAIR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MDCRKMVRFSYSVIWIMAISKAFELGLVAGLGHQEFARPSRGDLAFRDDSIWPQEEPAIR 60

Qy         61 PRSSQRVLPMGIQHSKELNRTCCLNGGTCMLESFCACPPSFYGRNCEHDVRKENCGSVPH 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 PRSSQRVLPMGIQHSKELNRTCCLNGGTCMLESFCACPPSFYGRNCEHDVRKENCGSVPH 120

Qy        121 DTWLPKKCSLCKCWHGQLRCFPQAFLPGCDGLVMDEHLVASRTPELPPSARTTTFMLAGI 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 DTWLPKKCSLCKCWHGQLRCFPQAFLPGCDGLVMDEHLVASRTPELPPSARTTTFMLAGI 180

Qy        181 CLSIQSYY 188
              ||||||||
Db        181 CLSIQSYY 188
```

RESULT 11
AAW25667
ID AAW25667 standard; protein; 188 AA.
XX
AC AAW25667;
XX
DT 25-MAR-2003 (revised)
DT 04-NOV-1997 (first entry)
XX
DE Protein encoded by CRIPTO-related gene, CR-3.
XX
KW CRIPTO-related gene; CR-3; epidermal growth factor; EGF; TGF-alpha;
KW amphiregulin; tumour specific marker; colon cancer cell line;
KW colorectal tumour; mesenchyme; epithelial cell.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Misc-difference 7
FT /note= "Ala>Val mutation"
FT Misc-difference 22
FT /note= "Val>Ala mutation"
FT Misc-difference 43
FT /note= "Tyr>Asp mutation"
FT Misc-difference 68
FT /note= "Pro>Leu mutation"
FT Misc-difference 86
FT /note= "Gly>Glu mutation"
FT Misc-difference 178
FT /note= "Val>Ala mutation"
XX
PN US5650285-A.
XX
PD 22-JUL-1997.
XX
PF 05-JUN-1995; 95US-00463335.
XX
PR 23-AUG-1991; 91US-00749001.
PR 17-NOV-1993; 93US-00154198.
XX
PA (USSH) US DEPT HEALTH & HUMAN SERVICES.
XX
PI Persica MG, Salomon DS;

XX
DR WPI; 1997-384668/35.
DR N-PSDB; AAT80987.
XX
PT Assays for CRIPTO-related gene product CR-3 - used in studies on the
PT regulation of the proliferation, differentiation and transformation of
PT cells.
XX
PS Claim 2; Fig 2; 25pp; English.
XX
CC This sequence is encoded by the CRIPTO-related gene, CR-3. The CR-3 gene
CC sequence is identical to the human CRIPTO gene with the exception of
CC eight base pair substitutions that give rise to six amino acid changes.
CC CR-3 exhibits partial amino acid sequence homology and a tertiary
CC structure within a 38 amino acid region similar to the epidermal growth
CC factor (EGF) supergens family that includes EGF, TGF-alpha and
CC amphiregulin. Expression of CR-3 may serve as a tumour specific marker as
CC it is expressed in several human colon cancer cell lines and possibly in
CC human colorectal tumours. The assay of the amount of CR-3 in a sample can
CC be used in studies on the regulation of the proliferation,
CC differentiation, and transformation of various mesenchymal and epithelial
CC cells. Study of the expression of CR-3 may also be used in the diagnosis,
CC prognosis and treatment of tumours. (Updated on 25-MAR-2003 to correct PF
CC field.)

```
  Query Match             98.6%;  Score 1033;  DB 2;  Length 188;
  Best Local Similarity   98.9%;  Pred. No. 1e-83;
  Matches  186;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy          1 MDCRKMVRFSYSVIWIMAISKAFELGLVAGLGHQEFARPSRGDLAFRDDSIWPQEEPAIR 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MDCRKMVRFSYSVIWIMAISKAFELGLVAGLGHQEFARPSRGDLAFRDDSIWPQEEPAIR 60

Qy         61 PRSSQRVLPMGIQHSKELNRTCCLNGGTCMLESFCACPPSFYGRNCEHDVRKENCGSVPH 120
              |||||||||||||||||||||||| ||||| ||||||||||||||||||||||||||||
Db         61 PRSSQRVLPMGIQHSKELNRTCCLNEGTCMLGSFCACPPSFYGRNCEHDVRKENCGSVPH 120

Qy        121 DTWLPKKCSLCKCWHGQLRCFPQAFLPGCDGLVMDEHLVASRTPELPPSARTTTFMLAGI 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 DTWLPKKCSLCKCWHGQLRCFPQAFLPGCDGLVMDEHLVASRTPELPPSARTTTFMLAGI 180

Qy        181 CLSIQSYY 188
              ||||||||
Db        181 CLSIQSYY 188
```

RESULT 3
US-10-945-853-4
; Sequence 4, Application US/10945853
; Publication No. US20050255117A1
; GENERAL INFORMATION:
; APPLICANT: Biogen, Inc.
; APPLICANT: Sanicola-Nadel, Michele
; APPLICANT: Adkins, Heather
; APPLICANT: Miklasz, Steven Donald
; APPLICANT: Rayhorn, Paul
; APPLICANT: Schiffer, Susan Gail
; APPLICANT: Williams, Kevin
; TITLE OF INVENTION: Cripto-Specific Antibodies

; FILE REFERENCE: BGNA117CPPCCN
; CURRENT APPLICATION NUMBER: US/10/945,853
; CURRENT FILING DATE: 2004-09-20
; PRIOR APPLICATION NUMBER: PCT/US02/31462
; PRIOR FILING DATE: 2002-10-01
; PRIOR APPLICATION NUMBER: PCT/US02/11950
; PRIOR FILING DATE: 2002-04-17
; PRIOR APPLICATION NUMBER: 60/286,782
; PRIOR FILING DATE: 2001-04-26
; PRIOR APPLICATION NUMBER: 60/293,020
; PRIOR FILING DATE: 2001-05-17
; PRIOR APPLICATION NUMBER: 60/301,091
; PRIOR FILING DATE: 2001-06-26
; PRIOR APPLICATION NUMBER: 60/367,002
; PRIOR FILING DATE: 2002-03-22
; NUMBER OF SEQ ID NOS: 9
; SEQ ID NO 4
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-945-853-4

```
  Query Match             100.0%;  Score 104;  DB 5;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 2e-08;
  Matches   17;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 CPPSFYGRNCEHDVRKE 17
              |||||||||||||||||
Db          1 CPPSFYGRNCEHDVRKE 17
```

1: J Cancer Res Clin Oncol. 2001 Oct;127 Suppl 2:R20-6.

Keyhole limpet hemocyanin conjugate vaccines against cancer: the Memorial Sloan Kettering experience.

Musselli C, Livingston PO, Ragupathi G.

Memorial Sloan Kettering Cancer Center, Department of Tumor Vaccinology, New York, NY 10021, USA.

Passively administered and actively induced antibodies have been associated with the eradication of circulating tumor cells and micrometastases in mice and humans. We have identified a series of cell surface carbohydrate and peptide antigens on melanomas, sarcomas, and cancer of the breast, prostate. ovary, and lung tissues. We found that breaking tolerance toward these tumor antigens was best achieved using vaccines containing antigens chemically conjugated to keyhole limpet hemocyanin (KLH) plus a potent immunological adjuvant (QS-21). To date, by using this approach to vaccination. antibodies have been induced in patients against glycolipid antigens GM2, GD2, GD3, FucosylGM1, Globo H, and Lewis Y, and glycoprotein (mucin) antigens Tn, sialyl Tn. TF, and MUC1. More recently, in a comparative study we investigated the T cell response induced by MUCI-KLH conjugates. Although a MUC1-specific T cell response was not consistently detected in any patient, the role of KLH in orienting the cytokine environment was crucial. We were able to confirm that KLH in these conjugate vaccines induces a Th1 T cell response as demonstrated by the high anti-KLH INF-gamma secretion and the IgGI and IgG3 subclasses of this high titer IgG antibodies induced. Clinical trials using KLH conjugated glycolipid and glycoprotein vaccines, are currently ongoing. These range from phase I/II single antigens trials with glycosilated MUC1, polysialic acid, synthetic Fucosyl GMI and GD2, to phase II trials with a polyvalent vaccine containing six or seven antigens. Randomized phase II trials with polyvalent vaccines are planned for initiation in 2001-2002 in patients with ovarian, breast, and prostate cancer.